Teva Pharmaceutical (NYSE: TEVA) reported Q2 EPS of $1.20, in-line with the analyst estimate of $1.20. Revenue for the quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE